海通证券股份有限公司关于采纳科技股份有限公司 2023 年半年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：采纳科技股份有限公司 | | --- | --- | | 保荐代表人姓名：钟祝可 | 联系电话：021-23185939 | | 保荐代表人姓名：张刚 | 联系电话：021-23187055 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 不适用 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于 防止关联方占用公司资源的制度、募集资金管理制度、 内控制度、内部审计制度、关联交易制度） | 是 | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4、公司治理督导情况 | | | （1）列席公司股 ...

证券代码：301122 证券简称：采纳股份 公告编号：2023-073 采纳科技股份有限公司 第三届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、审议通过了《关于 2023 年半年度募集资金存放与实际使用情况的专项报 告》 经审议，该专项报告主要从募集资金的存放和实际使用情况等方面反应了 2023 年上半年募集资金的具体情况。 1 / 2 表决结果：赞成 9 票，反对 0 票，弃权 0 票。 一、董事会会议召开情况 采纳科技股份有限公司（以下简称"公司"）第三届董事会第二次会议通知 于 2023 年 8 月 11 日以邮件、电话等方式向各位董事发出，会议于 2023 年 8 月 23 日以现场会议结合通讯形式，在江苏省江阴市祝塘镇环西路 23 号采纳医疗办 公楼一楼会议室召开。本次会议由公司董事长陆军先生主持，会议应出席董事 9 人，实际出席董事 9 人（其中以通讯表决方式出席会议的董事人数 4 人，分别 为：侯鹏先生、刘斌先生、王尚虎先生、夏立扬先生），公司监事及部分高级管 理人员列席了会议。本次会议的召集、召开及表决符合《中 ...

| | | 占用方与上 | 上市公司核算的 | 2023 年期初占 | 2023 年半年度占 | 2023 年半年度 | 2023 年半年度 | 2023 年 | 6 月末 | 占用形成 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 市公司的关 | | | 用累计发生金额 | 占用资金的利 | 偿还累计发生 | | | | 占用性质 | | | | 联关系 | 会计科目 | 用资金余额 | （不含利息） | 息（如有） | 金额 | 占用资金余额 | | 原因 | | | 控股股东、实际控制人及 | - | - | - | - | - | - | - | - | | - | 非经营性 | | 其附属企业 | - | - | - | - | - | - | - | - | | - | 非经营性 | | 小计 | - | - | - | - | - | - | - | - | | - | - | | 前控股股东、实际控制人 | - | - | - | - | ...

证券代码：301122 证券简称：采纳股份 公告编号：2023-071 采纳科技股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 单位：人民币万元 | | 项目 | | 序号 | 金额 | | --- | --- | --- | --- | --- | | 募集资金净额 | | A | | 109,726.24 | | 置换前期投入项目金额 | | B | 386.63 | | --- | --- | --- | --- | | 本期发生额 | 项目投入 | C1 | 8,803.33 | | | 永久补充流动资金划出金额 | C2 | 20,000.00 | | | 利息收入净额 | C3 | 943.76 | | 以前年度发生额 | 项目投入 | D1 | 12,134.07 | | | 永久补充流动资金划出金额 | D2 | 25,000.00 | | | 利息收入净额 | D3 | 1,400.58 | | 截至期末发生额 | 项目投入 | E1=B+C1+D1 | 21,324.03 | ...

证券代码：301122 证券简称：采纳股份 采纳科技股份有限公司 投资者关系活动记录表 编号：2023-03 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 ■现场参观 □其他（请文字说明其他活动内容） 投资者关系活动 类别 天风证券：张雪 中泰自营：彭婷 红筹投资：葛云霄 汇森投资：庞雨东 参与单位名称及 东吴资管：陈韬 巨杉资产：何川 人员姓名 湘财基金：张泉 崇山投资：覃欣 永赢基金：张蕊 慎知资产：高岳 东方阿尔法基金：程可 时间 2023 年 6 月 6 日 地点 公司会议室 上市公司接待人 员姓名 董事会秘书：陆维炜 证券事务代表：吴大松 1、请介绍公司二期项目建造的进展情况？ 答：公司位于华士镇澄鹿路的二期项目拟规划厂房 9 万平 米，目前主体建筑已完工，现处于装修阶段，部分设备已陆续 进厂待安装调试。根据项目实施计划及工程进度，预计在 2023 年下半年可陆续释放部分产能，二期项目主要以生产医疗器械 投资者关系活动 产品为主。 主要内容介绍 2、二期项目产能释放后与公司订单是否匹配？ 答：公司产品目前覆盖三大板块：医疗器械板块、动物器 械板块、实验室耗材板块。 ...

Financial Performance - The company's revenue for Q1 2023 was ¥66,839,280.56, representing a decrease of 52.79% compared to ¥141,589,832.60 in the same period last year[5] - Net profit attributable to shareholders was ¥15,878,407.77, down 59.62% from ¥39,324,380.01 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 66,839,280.56, a decrease of 52.8% compared to CNY 141,589,832.60 in the same period last year[19] - Net profit for Q1 2023 was CNY 15,878,407.77, a decline of 59.6% compared to CNY 39,324,380.01 in Q1 2022[20] - The total comprehensive income for the first quarter was CNY 15,878,407.77, a decrease from CNY 39,324,380.01 in the previous period[21] - Basic and diluted earnings per share for the quarter were both CNY 0.17, down from CNY 0.46 in the previous period[21] Cash Flow and Assets - The net cash flow from operating activities increased significantly to ¥38,212,822.55, a 5,374.04% improvement from -¥724,544.89 in the previous year[5] - The total cash and cash equivalents at the end of Q1 2023 amounted to CNY 282,245,196.54, down from CNY 355,590,390.56 at the beginning of the year, representing a decrease of approximately 20.5%[15] - The ending balance of cash and cash equivalents was CNY 282,245,196.54, down from CNY 802,495,998.92 in the previous period[23] - Cash inflow from investment activities totaled CNY 377,945,720.28, compared to CNY 100,200,000.00 in the previous period[23] - Cash outflow from investment activities was CNY 487,061,256.80, down from CNY 527,604,403.50 in the previous period[23] - The net cash flow from investment activities was negative CNY 109,115,536.52, an improvement from negative CNY 427,404,403.50 in the previous period[23] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,847,147,895.30, a slight increase of 0.20% from ¥1,843,375,847.83 at the end of the previous year[5] - Total liabilities decreased to CNY 94,926,248.64 from CNY 107,032,608.94, indicating a reduction in financial obligations[17] - The company's total equity increased to CNY 1,752,221,646.66 from CNY 1,736,343,238.89, showing a positive trend in shareholder value[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,109, with the top shareholder holding 28.29% of the shares[10] - The top shareholder, Jiangyin New Guolian Group Co., Ltd., holds 3,157,900 shares, representing 3.36% of the total shares[12] - The company has a total of 10 major shareholders, with the largest holding being 6,000,000 shares by Zhao Hong, accounting for 6.38%[12] Investment and Expenses - The company reported a significant increase in investment income, which rose by 2,056.02% to ¥6,568,470.28, attributed to returns from newly purchased financial products[9] - The company experienced a 601.03% increase in financial expenses, totaling ¥1,067,454.17, mainly due to increased foreign exchange losses[9] - Research and development expenses were CNY 4,784,955.79, slightly down from CNY 4,889,125.57 in the previous year[20] Future Outlook and Strategy - The company has not provided specific future outlook or performance guidance for the upcoming quarters[14] - The company plans to focus on market expansion and new product development as part of its future strategy[20] Other Information - The company has not disclosed any new product developments or technological advancements during this quarter[14] - There are no updates on market expansion or mergers and acquisitions in the current report[14] - The first quarter report was not audited[24]

Financial Performance - The company's operating revenue for 2022 was ¥465,485,537.41, representing a 5.30% increase compared to ¥442,051,932.24 in 2021[21]. - Net profit attributable to shareholders for 2022 was ¥161,868,649.81, a 23.86% increase from ¥130,681,695.99 in 2021[21]. - The net profit after deducting non-recurring gains and losses was ¥139,054,676.08, up 10.92% from ¥125,366,249.94 in 2021[21]. - The total assets at the end of 2022 reached ¥1,843,375,847.83, a significant increase of 200.90% from ¥612,622,396.12 at the end of 2021[21]. - The net assets attributable to shareholders increased by 240.38% to ¥1,736,343,238.89 from ¥510,124,479.38 in 2021[21]. - The company reported a basic earnings per share of ¥1.76, down 4.86% from ¥1.85 in 2021[21]. - The weighted average return on equity decreased to 10.28% from 29.38% in 2021, a decline of 19.10%[21]. - The company experienced a net cash flow from operating activities of ¥138,881,985.74, which is a decrease of 13.23% compared to ¥160,053,823.98 in 2021[21]. Market Position and Industry Insights - The company is positioned in the specialized equipment manufacturing industry, focusing on medical devices, animal instruments, and laboratory consumables[30]. - The global market for injection and puncture products is projected to grow from $14.58 billion in 2019 to $25.7 billion by 2026, with a compound annual growth rate of 8.5%[32]. - The global veterinary vaccine sales reached approximately $6.935 billion in 2018, with a year-on-year growth of 5.11%[35]. - The global veterinary injection and puncture device market grew from $2.65 billion in 2014 to $3.37 billion in 2019, with a compound annual growth rate (CAGR) of 5.0%[35]. - The Chinese veterinary injection and puncture device market increased from ¥1.76 billion in 2014 to ¥2.47 billion in 2019, with a CAGR of 7.0%[36]. - The market size of China's veterinary injection device market is expected to reach ¥3.51 billion by 2024[36]. - The global laboratory consumables market grew from $28.341 billion in 2016 to $51.233 billion in 2021, with an expected annual growth rate of 15%[39]. - The company holds a leading position in the domestic veterinary injection device market, ranking first with a significant market share in 2019[42]. Research and Development - The company has established a research and development system focused on market needs, with dedicated centers for veterinary puncture devices and safety self-destruct syringes[62]. - The company is developing a safety indwelling needle aimed at reducing patient discomfort and preventing the spread of bloodborne diseases, with product molds already completed and CE registration in progress[87]. - A safety structure syringe is under development, designed to prevent accidental injuries and improve product competitiveness, with design and sample production phases ongoing[87]. - The company has obtained 26 FDA 510K registrations for its products, leading the industry in this regard[90]. - The company's R&D investment reached CNY 19,733,928.29 in 2022, accounting for 4.24% of its operating revenue[89]. - The number of R&D personnel increased to 118 in 2022, representing a growth of 18.07% compared to 2021[89]. Production and Quality Control - The company maintains a strict quality control process throughout production, adhering to ISO13485 and FDA standards[52]. - The company has established a comprehensive quality management system, certified by ISO13485 and MDSAP[64]. - The company has a production facility exceeding 68,000 square meters, with over 40,000 square meters meeting GMP standards[67]. - The company emphasizes a production model based on customer orders, adopting a "sales-driven production" approach to ensure product quality and efficiency[52]. Cash Flow and Investment Activities - The total cash inflow from operating activities in 2022 was approximately ¥512.06 million, an increase of 8.19% compared to ¥473.28 million in 2021[98]. - The total cash outflow from operating activities in 2022 was approximately ¥373.18 million, representing a 19.14% increase from ¥313.23 million in 2021[98]. - The cash inflow from investment activities surged to approximately ¥1.35 billion in 2022, a dramatic increase of 14,052.37% compared to ¥9.52 million in 2021[98]. - The cash outflow from investment activities in 2022 was approximately ¥2.34 billion, a significant rise of 1,545.29% from ¥142.15 million in 2021[98]. - The net cash flow from investment activities was approximately -¥991.91 million in 2022, worsening from -¥132.64 million in 2021, indicating a 647.84% increase in negative cash flow[98]. Governance and Compliance - The company emphasizes information disclosure, adhering to legal requirements to provide accurate and timely information to all shareholders[144]. - The company maintains an independent governance structure, ensuring operational independence from its controlling shareholder and actual controller[143]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[140]. - The supervisory board is composed of 3 members, including 1 employee representative, fulfilling its responsibilities to protect shareholder interests[142]. Employee Management and Compensation - The total number of employees at the end of the reporting period was 689, with 352 in the parent company and 337 in major subsidiaries[182]. - The company has a competitive salary policy, combining base salary and performance-based pay, with salaries determined by job importance and company performance[184]. - The company plans to attract high-level technical, management, and marketing talents through competitive compensation and training programs over the next three years[185]. - The total pre-tax remuneration for directors, supervisors, and senior management amounted to CNY 3.0655 million[172]. Future Strategies and Goals - The company plans to increase R&D investment to enhance product competitiveness and profitability, aiming to mitigate risks from potential trade tensions and tariffs[128]. - The company aims to expand its product offerings and enhance competitiveness through innovative R&D initiatives[88]. - The company is focused on expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[175]. - The company plans to enhance its online sales platform, aiming for a 40% increase in e-commerce revenue in 2023[175].

证券代码：301122 证券简称：采纳股份 公告编号：2023-025 采纳科技股份有限公司 关于举办 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 11 日在巨潮 资讯网上披露了《2022 年年度报告全文》及《2022 年年度报告摘要》。为便于 广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2023 年 04 月 20 日（星期四）15:00-17:00 在"价值在线"（www.ir-online.cn）举办 公司 2022 年度业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意见 和建议。 一、说明会召开的时间、地点和方式 会议召开时间：2023 年 04 月 20 日（星期四）15:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 二、参加人员 出席本次年度业绩说明会的人员：董事长兼总经理陆军先生、董事会秘书陆 维炜先生、财务负责人查凌云女士、独立董事刘斌先生、保荐代表人钟 ...